Data / Form D filings / NextCure, Inc.
NextCure, Inc.: Form D filings
NextCure, Inc., a biotechnology company in Beltsville, MD, filed 3 Form D notices with the SEC between 2016 and 2025. The latest, on December 10, 2025, reports $21.5 million sold of a $21.5 million offering to 12 investors.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 9000 VIRGINIA MANOR ROAD, SUITE 200, Beltsville, MD, 20705
- Phone
- (240) 399-4900
- Industry
- Biotechnology
- Entity type
- Corporation
- Incorporated in
- Delaware
- Revenue range
- No Revenues
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 1661059
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Dec 10, 2025 | New notice | $21,500,000 | $21,500,000 | 12 | Nov 12, 2025 | sec.gov | |
| Nov 19, 2018 | New notice | $93,432,873 | $93,432,873 | 22 | Nov 5, 2018 | sec.gov | |
| Jan 11, 2016 | New notice | $67,000,000 | $15,000,000 | $52,000,000 | 7 | Dec 29, 2015 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Timothy G. Mayer | Executive Officer | |
| Michael Richman | Executive Officer, Director | |
| Elaine V. Jones | Director | |
| Udayan G. Guha | Executive Officer | |
| Anne G. Borgman | Director | |
| Steven P. Cobourn | Executive Officer | |
| David P. Kabakoff | Director | |
| Sourav G. Kundu | Executive Officer | |
| Ellen G. Feigal | Director | |
| Stephen G. Webster | Director | |
| John G. Houston | Director | |
| Kevin G. Shaw | Executive Officer |
Other biotechnology companies in Maryland that filed recently
- Accufy Diagnostics, Inc. $2 million · Oct 28, 2026
- OS Therapies Inc $7.2 million · Oct 23, 2026
- Kaigene, Inc. $55 million · Oct 14, 2026
- Templar Nova, Inc. $7 million · Oct 7, 2026
- Monocacy Therapeutics Inc. $25,000 · Oct 7, 2026
- Seraxis Holdings, Inc. $10 million · Sep 24, 2026
Every Form D from the week of Dec 8, 2025 · All recent filings in Maryland · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what NextCure, Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.